It is currently being evaluated in a phase I dose escalation and expansion study (NCT05786924) for its safety and anti-tumor activity in patients with class I, II, and III BRAF mutant or KRAS/NRAS mutant advanced solid tumors, including colorectal cancer [59]. Here, BRAF is linked to neoplasm.